Clinical Trials
11 results for Bladder Cancer
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
- Condition: Bladder Cancer
- Study ID: NCT02625961
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU16-243
- Condition: Urothelial Carcinoma, Bladder Cancer
- Intervention: Drug: Durvalumab, Radiation: External Beam Radiotherapy (EBRT), Biological: Bacillus Calmette-Guérin (BCG)
- Study ID: NCT03317158
Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer
- Condition: Bladder Cancer
- Intervention: Drug: Pembrolizumab (MK-3475)
- Study ID: NCT03504163
Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study
- Condition: Superficial Bladder Cancer
- Intervention: Drug: abnobaVISCUM 900, Drug: Mitomycin C
- Study ID: NCT02106572
Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma
- Condition: Bladder Cancer
- Intervention: Drug: BCG instillation therapy, Drug: Sequential BCG and EMDA mitomycin C
- Study ID: NCT03664869
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Condition: Bladder Urothelial Carcinoma In Situ, High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Infiltrating Bladder Mixed Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Study ID: NCT04164082
A Phase II Clinical Study of Intravesical Photodynamic Therapy in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Or Patients Who Are Intolerant to BCG Therapy ("Study").
- Condition: Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
- Intervention: Combination Product: TLD-1433 Bladder infusion and Photodynamic Therapy
- Study ID: NCT03945162
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
- Condition: Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Study ID: NCT05375903
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
- Condition: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
- Study ID: NCT06111235
Phase II Trial of Intravesical Gemcitabine in Patients With Nonmuscle Invasive Bladder Cancer With or Without Prior Bacillus Calmette-Guérin Therapy
- Condition: Urinary Bladder Cancer
- Study ID: NCT05644041
A Phase 3 Study of CG0070 in Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
- Condition: Non Muscular Invasive Bladder Cancer
- Study ID: NCT04452591